$204.00
Overview
Tirzepatide is the first dual GIP and GLP-1 receptor agonist — a molecule that activates two distinct incretin hormone pathways at once for a synergistic metabolic effect that neither pathway achieves alone. It is the active ingredient in FDA-approved Mounjaro and Zepbound. This 10mg research vial represents the maintenance and upper-range dose used in established protocols.
What it does
Tirzepatide works across five simultaneous pathways: central appetite suppression via hypothalamic GLP-1 and GIP receptor activation, increased fat oxidation and thermogenesis through GIP receptor activity in adipose tissue, delayed gastric emptying that extends satiety and blunts post-meal glucose spikes, glucose-dependent insulin stimulation that avoids hypoglycaemia risk, and altered lipid partitioning in adipocytes that shifts the fat stored-to-fat-burned ratio.
Research areas
Obesity and metabolic syndrome · Type 2 diabetes management · Body composition and visceral fat reduction · Cardiovascular risk reduction · Glucose and insulin regulation research
Key facts
| Form | Lyophilised powder — requires reconstitution with bacteriostatic water |
| Storage | Lyophilised: -20°C. Reconstituted: 2–8°C, use within 28 days |
| Purity | ≥99% — third-party COA verified, batch-specific documentation included |
For research use only. Not for human consumption. This product is not approved for human use by the FDA or any regulatory body.
